Streetbeat News

Analyst Ratings

SARK

SQ

TARK

Block, Inc (NYSE:SQ) is experiencing a surge over 5% ahead of its Q4 earnings, following a Q3 earnings beat. Analysts predict Q4 EPS of 59 cents on $5.699 billion revenue. Wedbush upgraded Block's rating to Outperform with a price target of $90. For diversification, investors might consider AXS 2X Innovation ETF (NASDAQ:TARK) and AXS Short Innovation Daily ETF (NASDAQ:SARK), related to ARK Innovation ETF's performance, which includes Block. Technical analysis shows Block trading neutrally with potential for both bullish and bearish reactions post-earnings.

Portfolio Pulse from Melanie Schaffer

February 22, 2024 | 7:47 pm

EXAS

Canaccord Genuity analyst Kyle Mikson maintains a Buy rating on Exact Sciences (NASDAQ:EXAS) but lowers the price target from $100 to $90.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 7:39 pm

ARM

INTC

MSFT

UMC

Intel Corp (NASDAQ:INTC) hosted Intel Foundry Direct Connect, where CEO Pat Gelsinger outlined the future of Intel, including the division into Intel Products and Intel Foundry. The event detailed updates to the Foundry services roadmap, including new business units, volume production updates, and partnerships. Notably, Intel is expanding its foundry services and has design wins with Microsoft Corp (NASDAQ:MSFT) and Arm Holdings Plc (NASDAQ:ARM) for SoCs. Additionally, Intel announced a partnership with United Microelectronics Corp (NYSE:UMC) for 12nm production. Despite these developments, Oppenheimer analyst Rick Schafer maintains a Perform rating on INTC, citing the company's ongoing efforts to achieve process leadership and foundry ambitions.

Portfolio Pulse from Anusuya Lahiri

February 22, 2024 | 7:37 pm

BBWI

Telsey Advisory Group analyst Dana Telsey maintains an Outperform rating on Bath & Body Works, Inc. (NYSE:BBWI) with a price target of $50, ahead of their Q4 earnings report. Sales are expected to decline 1.9% YOY to $2.833 billion, with a same-store sales decline of 5%. However, gross margin is projected to improve by over 100 bps to 44.4%, driven by merchandise margin improvement and cost optimization. Operating margin is expected to be 22.6%, slightly below market expectations. The company is also on track to generate $200 million in annual cost savings from its profit improvement plan.

Portfolio Pulse from Nabaparna Bhattacharya

February 22, 2024 | 7:36 pm

WDAY

Keybanc analyst Jason Celino maintains an Overweight rating on Workday (WDAY) and raises the price target from $310 to $330.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 7:36 pm

NVDA

Keybanc analyst John Vinh has maintained an Overweight rating on NVIDIA (NASDAQ:NVDA) and increased the price target from $740 to $1100, indicating a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 7:34 pm

FIVN

Keybanc analyst Thomas Blakey maintains an Overweight rating on Five9 (NASDAQ:FIVN) but lowers the price target from $93 to $86.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 7:31 pm

ADSK

Keybanc analyst Jason Celino has maintained an Overweight rating on Autodesk (NASDAQ:ADSK) and increased the price target from $265 to $275. This adjustment reflects a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 7:29 pm

COF

DFS

Discover Financial Services (DFS) was downgraded by RBC Capital Markets analyst Jon G. Arfstrom to Sector Perform from Outperform with a new price target of $140, following a merger deal with Capital One Financial Corp (COF). The deal offers Discover shareholders a 26.6% premium, with 1.0192 shares of COF for each DFS share. The merger is expected to be over 15% accretive to adjusted non-GAAP EPS and generate $2.7 billion in pre-tax synergies by 2027. The analyst sees the merger as compelling, despite past challenges faced by Discover, including compliance issues and leadership transitions.

Portfolio Pulse from Lekha Gupta

February 22, 2024 | 7:28 pm

NVCR

HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on NovoCure (NASDAQ:NVCR) and raises the price target from $21 to $22.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 7:24 pm